Capricor Therapeutics announced the commencement of a proposed underwritten public offering of shares of its common stock. The company intends to use the net proceeds from this offering on the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes. Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the public offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Tesla lower after ‘underwhelming’ robotaxi launch event: Morning Buzz
- Capricor Therapeutics announces long-term data from HOPE-2 OLE study
- Capricor Therapeutics price target raised to $77 from $40 at H.C. Wainwright
- DOJ may push for breakup of Google: Morning Buzz
- Capricor Advances Duchenne Treatment with FDA Submission